Literature DB >> 17609639

How well does "evidence-based" medicine help neurologists care for individual patients?

Louis R Caplan1.   

Abstract

The advocates of evidence-based medicine have established a clear, unambiguous requirement for what they consider credible evidence: the randomized, controlled trial and systematic reviews of several or many randomized, controlled trials. However, evidence from therapeutic trials cannot always be applied to the care of individual patients. These studies yield information only on the likely benefit of a particular treatment strategy among a large group of often heterogeneous patients with a given condition. Some trials may show statistically significant positive results for a certain therapy, but these results may be of little or no practical benefit for most patients with the condition studied. Other studies may show that a certain treatment is beneficial to most patients, although it may have serious risks and cause harm in others with the same condition. To be therapeutically useful, a trial must study specific, well-defined, and quantifiable conditions with important and readily recognized and defined endpoints. More importantly, physicians should spend more time finding out what is wrong with each patient and getting to know his or her circumstances, family situations, psychosocial and economic stresses, thoughts, fears, biases, and wishes.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17609639

Source DB:  PubMed          Journal:  Rev Neurol Dis        ISSN: 1545-2913


  5 in total

1.  An ethical hierarchy for decision making during medical emergencies.

Authors:  Patrick D Lyden; Brett C Meyer; Thomas M Hemmen; Karen S Rapp
Journal:  Ann Neurol       Date:  2010-04       Impact factor: 10.422

2.  Is Alzheimer's Prevention Possible Today?

Authors:  Richard Isaacson
Journal:  J Am Geriatr Soc       Date:  2017-08-28       Impact factor: 5.562

3.  Selecting Patients for Intra-Arterial Therapy in the Context of a Clinical Trial for Neuroprotection.

Authors:  Patrick Lyden; Sara Weymer; Chris Coffey; Merit Cudkowicz; Samantha Berg; Sarah O'Brien; Marc Fisher; E Clarke Haley; Pooja Khatri; Jeff Saver; Steven Levine; Howard Levy; Marilyn Rymer; Lawrence Wechsler; Ashutosh Jadhav; Elizabeth McNeil; Salina Waddy; Kent Pryor
Journal:  Stroke       Date:  2016-11-01       Impact factor: 7.914

4.  Guidelines: is bigger better? A review of SIGN guidelines.

Authors:  A Gordon Baird; James R Lawrence
Journal:  BMJ Open       Date:  2014-02-05       Impact factor: 2.692

5.  Minimal clinically important difference in Parkinson's disease as assessed in pivotal trials of pramipexole extended release.

Authors:  Robert A Hauser; Mark Forrest Gordon; Yoshikuni Mizuno; Werner Poewe; Paolo Barone; Anthony H Schapira; Olivier Rascol; Catherine Debieuvre; Mandy Fräßdorf
Journal:  Parkinsons Dis       Date:  2014-04-01
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.